CompletedPhase 1

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Switzerland72 participantsStarted 2008-06

Plain-language summary

This trial is designed to evaluate safety, tolerability and immunogenicity of a bedside mixing formulation of adjuvanted influenza vaccines.

Who can participate

Age range18 Years – 39 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy 18 to 39 year old males and females who are in good health and have provided informed consent prior to enrollment Exclusion Criteria: * serious medical conditions * allergies to vaccine components, including but not limited to egg/chicken products * reduced immune function * recent use of immunosuppressive therapy * recent use of influenza vaccine

What they're measuring

Safety as measured through local and systemic reactions and efficacy (immunogenicity) as measured by antibody titers.

Timeframe: 36 Days

Trial details

NCT IDNCT00735020

SponsorNovartis Vaccines

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-08

View on ClinicalTrials.gov More Influenza trials